HJB - Your Trusted Biologics CDMO Partner

HJB, CDMO, biologics, HJB Bio, hjbbio, China CDMO, 杭州奕安济世, Just Bio, Just biotherapeutics, HJB bio, HJB China, Hangzhou HJB

HJB - Your Trusted Biologics CDMO Partner

Cn
Company News

06Jun, 2018

HJB Secures $35 Million Series B+ Financing

Dedicated to innovative process and continuous manufacturing of biologics and providing high quality, reliable and efficient CDMO services to partners, HJB announced today the completion of a $35 million Series B+ financing round.

Hillhouse Capital (Hillhouse), a Beijing and Hong Kong-based investment firm, leads this financing, with participation by existing investors Temasek, Lilly Asia Ventures (LAV), ARCH Venture Partners, Taikang and BOCGI Zheshang Capital. Including this round, HJB has raised over $120 million in financing so far.

Since last year HJB has focused predominantly in 3 areas: the completion of the R&D Center and Manufacturing Facility located in Hangzhou, establishing its R&D and clinical development capabilities and building a world-class team by attracting top talents around the world.

HJB was originally founded in 2016 by former Amgen and Genentech executives in Hangzhou, China. With the state-of-the-art biomanufacturing and process development platform, HJB can develop and manufacture antibody and recombinant proteins at a reduced cost and accelerated speed while maintaining global quality standards. HJB also employs an experienced team of scientists and engineers in its sites in Hangzhou and Boston, and is led by seasoned executives from MNCs.

22Jan, 2018

HJB Opens R&D Center and GMP Manufacturing Facility to Develop Biologic Medicines Globally

HJB, an organization dedicated to expanding global access to important protein therapeutics, today held the grand opening ceremony for its R&D Center and Manufacturing Facility. Around 200 guests including business partners, investors and representatives from pharmaceutical companies were present to witness this historical moment.

Jonathan Y. Zhao, Founder and CEO of HJB, delivered a speech at the opening ceremony. He reviewed the progress HJB has made since its establishment, and stressed that “HJB has reached another important milestone. This is a great step towards our mission of expanding global access to biotherapeutics. We will further leverage the 3rd-generation biologics platform to develop and manufacture high quality biologics for patients around the world.”

Over the past two years, HJB has secured a total of USD 67 million in financing from Lilly Asia Ventures, ARCH Venture Partners, Temasek, Taikang, HEDA and other investors, and has grown rapidly. HJB completed the 140,000 sq.ft R&D Center and GMP Manufacturing Facility which will supply the global market with clinical and commercial product.

09Aug, 2017

HJB Secures $57 Million Series B Financing

Dedicated to innovative process and continuous manufacturing of biologics and providing high quality, reliable and efficient CDMO services to partners, HJB today announced the completion of its Series B funding round.

14Mar, 2017

HJB and G-CON Manufacturing Announce Strategic Collaboration

HJB and G-CON Manufacturing, Inc. today announced that the companies are working together on HJB’s state-of-the-art biologics facility in the Hangzhou Economic & Technology Development Area (HEDA) in China. The cGMP facility is expected to be completed and operational in early 2018.

This will be the first commercial facility for HJB. With cutting-edge technologies and the flexible and rapidly deployable PODs, HJB will be able to reduce time for development and manufacturing cost, while at the same time creates a new standard for bioprocessing industry facilities.

HJB was founded in 2014, dedicated to innovative process and continuous manufacturing of biologics and providing high quality, reliable and efficient CDMO services to partners. In this application PODs will be referred to as T-BLOC, representing the fully equipped processing units capable of running highly intensified bioprocesses.

Maik Jornitz, CEO and President of G-CON Manufacturing, stated, “Our flexible, compact PODular cleanroom systems are becoming an attractive and cost-efficient alternative for the industry, compared to traditional brick and mortar or stick built systems. We very much appreciate the teamwork together pursuing our facility innovation for HJB’s inaugural commercial scale facility. And we look very much forward to continuing the team work to help change the drug manufacturing paradigm.”

HJB’s facility will be in the Hangzhou Economic & Technology Development Area, an area founded in 1993 as one of China's first state level development zones. The HEDA is a international industrial, scientific and manufacturing zone producing a number of high value products including biologic drugs, microelectronics, mobile telecommunications, optical equipment products, automobile products, chemicals and computers.